Table 3.
COVID-19 outcomes in immune-mediated cases treated with CD20 inhibitors versus matched comparators.
| Outcomes | CD20 Inhibitor-Treated Immune-Mediated Cases (n=114) | Matched Comparators (n=559) |
|---|---|---|
| Hospitalization, n (%) | 35 (31) | 123 (22) |
| Total follow-up time (person-days) | 11658 | 62942 |
| Incidence rate/1000 days (95% CI) | 3.0 (2.0 to 4.0) | 2.0 (1.6 to 2.3) |
| Unadjusted HR (95% CI) | 1.32 (0.96 to 1.80) | Ref |
| Adjusted model 1 HR (95% CI)* | 1.24 (0.90 to 1.70) | Ref |
| Adjusted model 2 HR (95% CI) | 1.16 (0.85 to 1.60) | Ref |
| Adjusted model 3 HR (95% CI) | 0.88 (0.62 to 1.26) | Ref |
| Mechanical ventilation, n (%) | 6 (5) | 26 (5) |
| Total follow-up time (person-days) | 14755 | 78729 |
| Incidence rate/1000 days (95% CI) | 0.4 (0.1 to 0.7) | 0.3 (0.2 to 0.5) |
| Unadjusted HR (95% CI) | 1.10 (0.48 to 2.52) | Ref |
| Adjusted model 1 HR (95% CI) | 1.18 (0.50 to 2.79) | Ref |
| Adjusted model 2 HR (95% CI) | 1.49 (0.63 to 3.49) | Ref |
| Adjusted model 3 HR (95% CI) | 0.82 (0.36 to 1.87) | Ref |
| Death, n (%) | 12 (11) | 21 (4) |
| Total follow-up time (person-days) | 15818 | 84172 |
| Incidence rate/1000 days (95% CI) | 0.8 (0.3 to 1.2) | 0.2 (0.1 to 0.4) |
| Unadjusted HR (95% CI) | 2.86 (1.51 to 5.41) | Ref |
| Adjusted model 1 HR (95% CI) | 2.86 (1.52 to 5.37) | Ref |
| Adjusted model 2 HR (95% CI) | 2.42 (1.18 to 4.93) | Ref |
| Adjusted model 3 HR (95% CI)- | 2.16 (1.03 to 4.54) | Ref |
HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index, Ref, reference.
*
Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).